HC Wainwright & Co. initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $39.00

Jefferies initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $35.00

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

EFFECT - KINETA, INC./DE (0001445283) (Filer)

424B3 - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

S-3 - KINETA, INC./DE (0001445283) (Filer)

10-Q - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

8-K - KINETA, INC./DE (0001445283) (Filer)

SC 13G - KINETA, INC./DE (0001445283) (Subject)

SC 13D/A - KINETA, INC./DE (0001445283) (Subject)

SC 13G/A - KINETA, INC./DE (0001445283) (Subject)

SC 13G - KINETA, INC./DE (0001445283) (Subject)

SC 13D - KINETA, INC./DE (0001445283) (Subject)

SC 13G - KINETA, INC./DE (0001445283) (Subject)

SC 13G/A - KINETA, INC./DE (0001445283) (Subject)

SC 13G/A - KINETA, INC./DE (0001445283) (Subject)

SC 13G/A - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

SC 13G/A - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanity's previously announced proposed asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). Although the Registration Statement has not yet

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yu

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta's potential best-in-class VISTA blocking immunotherapy The combined company expects to close a PIPE financing in connection with the proposed merger Yumanity and Kineta to host webcast today at 8:30 a.m. EDT BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutic

YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles and a safety profile with no serious adverse events Conference call scheduled for 8:30 a.m. EST, Wednesday, November 10 BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease. The Company today reported that its lead product candidate, YTX-7739, in development for

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

4 - KINETA, INC./DE (0001445283) (Issuer)

BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer. "Michael's financial expertise combined with his proven ability to execute strategic and operational objectives will be invaluable to the Company," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "We are looking forward to Michael's contributions as we continue to pursue our vision of a future f

BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel. "We are delighted to welcome Devin as our general counsel at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "His experience providing legal counsel to public emerging life science companies will be important as we advance three clinical programs, move new innovative assets to t

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development. Dr. Verma brings more than 25 years of experience developing biotherapeutics in the field of neuroscience. "We are delighted to welcome Dr. Ajay Verma in the newly-created role of Head of R&D at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "As a clinically trained neurologist, A

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanity's previously announced proposed asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). Although the Registration Statement has not yet

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yu

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc., a private immuno-oncology company, to merge with Yumanity in an all-stock transaction that will advance Kineta's potential best-in-class VISTA blocking immunotherapy The combined company expects to close a PIPE financing in connection with the proposed merger Yumanity and Kineta to host webcast today at 8:30 a.m. EDT BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity") (NASDAQ:YMTX), a clinical-stage biopharmaceutic

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments. Recent Corporate Developments In February 2022, the Company announced its exploration of strategic alternatives to enhance shareholder value and engaged H.C. Wainwright as its exclusive financial advisor to assist in this process. The Company also announced a restructuring of the Company to preserve capital

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-year ended December 31, 2021 and provided an overview of the Company's recent corporate developments. "We continue to believe in the potential of YTX-7739, which may represent a major advancement in the treatment paradigm for Parkinson's patients," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity. "As previously announced, to preserve capital and optimize shareholder

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that it is exploring strategic alternatives with the goal of enhancing shareholder value. The Company has engaged H.C. Wainwright as its exclusive financial advisor to assist in this process. Potential strategic alternatives that may be considered as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Company. There can be

BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity's common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The options will have an exercise price of $2.19 per share, which is equal to the